307 related articles for article (PubMed ID: 22377180)
1. Prognostic factors for time to treatment failure and time to 12 months of remission for patients with focal epilepsy: post-hoc, subgroup analyses of data from the SANAD trial.
Bonnett L; Smith CT; Smith D; Williamson P; Chadwick D; Marson AG
Lancet Neurol; 2012 Apr; 11(4):331-40. PubMed ID: 22377180
[TBL] [Abstract][Full Text] [Related]
2. Antiepileptic drug monotherapy for epilepsy: a network meta-analysis of individual participant data.
Nevitt SJ; Sudell M; Weston J; Tudur Smith C; Marson AG
Cochrane Database Syst Rev; 2017 Dec; 12(12):CD011412. PubMed ID: 29243813
[TBL] [Abstract][Full Text] [Related]
3. Antiepileptic drug monotherapy for epilepsy: a network meta-analysis of individual participant data.
Nevitt SJ; Sudell M; Weston J; Tudur Smith C; Marson AG
Cochrane Database Syst Rev; 2017 Jun; 6(6):CD011412. PubMed ID: 28661008
[TBL] [Abstract][Full Text] [Related]
4. A randomised controlled trial examining the longer-term outcomes of standard versus new antiepileptic drugs. The SANAD trial.
Marson AG; Appleton R; Baker GA; Chadwick DW; Doughty J; Eaton B; Gamble C; Jacoby A; Shackley P; Smith DF; Tudur-Smith C; Vanoli A; Williamson PR
Health Technol Assess; 2007 Oct; 11(37):iii-iv, ix-x, 1-134. PubMed ID: 17903391
[TBL] [Abstract][Full Text] [Related]
5. Comparative persistence of antiepileptic drugs in patients with epilepsy: A STROBE-compliant retrospective cohort study.
Lai EC; Hsieh CY; Su CC; Yang YK; Huang CW; Lin SJ; Setoguchi S
Medicine (Baltimore); 2016 Aug; 95(35):e4481. PubMed ID: 27583857
[TBL] [Abstract][Full Text] [Related]
6. Antiepileptic drug monotherapy for epilepsy: a network meta-analysis of individual participant data.
Nevitt SJ; Sudell M; Cividini S; Marson AG; Tudur Smith C
Cochrane Database Syst Rev; 2022 Apr; 4(4):CD011412. PubMed ID: 35363878
[TBL] [Abstract][Full Text] [Related]
7. Lamotrigine versus carbamazepine monotherapy for epilepsy: an individual participant data review.
Nevitt SJ; Tudur Smith C; Weston J; Marson AG
Cochrane Database Syst Rev; 2018 Jun; 6(6):CD001031. PubMed ID: 29952431
[TBL] [Abstract][Full Text] [Related]
8. Lamotrigine versus carbamazepine monotherapy for epilepsy: an individual participant data review.
Nolan SJ; Tudur Smith C; Weston J; Marson AG
Cochrane Database Syst Rev; 2016 Nov; 11(11):CD001031. PubMed ID: 27841445
[TBL] [Abstract][Full Text] [Related]
9. Topiramate versus carbamazepine monotherapy for epilepsy: an individual participant data review.
Nevitt SJ; Sudell M; Tudur Smith C; Marson AG
Cochrane Database Syst Rev; 2019 Jun; 6(6):CD012065. PubMed ID: 31233229
[TBL] [Abstract][Full Text] [Related]
10. Topiramate versus carbamazepine monotherapy for epilepsy: an individual participant data review.
Nolan SJ; Sudell M; Tudur Smith C; Marson AG
Cochrane Database Syst Rev; 2016 Dec; 12(12):CD012065. PubMed ID: 27922722
[TBL] [Abstract][Full Text] [Related]
11. Lamotrigine versus levetiracetam or zonisamide for focal epilepsy and valproate versus levetiracetam for generalised and unclassified epilepsy: two SANAD II non-inferiority RCTs.
Marson AG; Burnside G; Appleton R; Smith D; Leach JP; Sills G; Tudur-Smith C; Plumpton CO; Hughes DA; Williamson PR; Baker G; Balabanova S; Taylor C; Brown R; Hindley D; Howell S; Maguire M; Mohanraj R; Smith PE
Health Technol Assess; 2021 Dec; 25(75):1-134. PubMed ID: 34931602
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and tolerability of the new antiepileptic drugs II: treatment of refractory epilepsy: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society.
French JA; Kanner AM; Bautista J; Abou-Khalil B; Browne T; Harden CL; Theodore WH; Bazil C; Stern J; Schachter SC; Bergen D; Hirtz D; Montouris GD; Nespeca M; Gidal B; Marks WJ; Turk WR; Fischer JH; Bourgeois B; Wilner A; Faught RE; Sachdeo RC; Beydoun A; Glauser TA; ; ;
Neurology; 2004 Apr; 62(8):1261-73. PubMed ID: 15111660
[TBL] [Abstract][Full Text] [Related]
13. Epilepsy in children: the evidence for new antiepileptic drugs.
Verdru P
Acta Neurol Scand Suppl; 2005; 181():17-20. PubMed ID: 16238703
[TBL] [Abstract][Full Text] [Related]
14. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial.
Marson AG; Al-Kharusi AM; Alwaidh M; Appleton R; Baker GA; Chadwick DW; Cramp C; Cockerell OC; Cooper PN; Doughty J; Eaton B; Gamble C; Goulding PJ; Howell SJ; Hughes A; Jackson M; Jacoby A; Kellett M; Lawson GR; Leach JP; Nicolaides P; Roberts R; Shackley P; Shen J; Smith DF; Smith PE; Smith CT; Vanoli A; Williamson PR;
Lancet; 2007 Mar; 369(9566):1000-15. PubMed ID: 17382827
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and tolerability of the new antiepileptic drugs I: treatment of new onset epilepsy: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society.
French JA; Kanner AM; Bautista J; Abou-Khalil B; Browne T; Harden CL; Theodore WH; Bazil C; Stern J; Schachter SC; Bergen D; Hirtz D; Montouris GD; Nespeca M; Gidal B; Marks WJ; Turk WR; Fischer JH; Bourgeois B; Wilner A; Faught RE; Sachdeo RC; Beydoun A; Glauser TA; ; ;
Neurology; 2004 Apr; 62(8):1252-60. PubMed ID: 15111659
[TBL] [Abstract][Full Text] [Related]
16. Newer antiepileptic drugs. Towards an improved risk-benefit ratio.
Patsalos PN; Sander JW
Drug Saf; 1994 Jul; 11(1):37-67. PubMed ID: 7917080
[TBL] [Abstract][Full Text] [Related]
17. The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial.
Marson AG; Al-Kharusi AM; Alwaidh M; Appleton R; Baker GA; Chadwick DW; Cramp C; Cockerell OC; Cooper PN; Doughty J; Eaton B; Gamble C; Goulding PJ; Howell SJ; Hughes A; Jackson M; Jacoby A; Kellett M; Lawson GR; Leach JP; Nicolaides P; Roberts R; Shackley P; Shen J; Smith DF; Smith PE; Smith CT; Vanoli A; Williamson PR;
Lancet; 2007 Mar; 369(9566):1016-26. PubMed ID: 17382828
[TBL] [Abstract][Full Text] [Related]
18. Carbamazepine versus phenobarbitone monotherapy for epilepsy: an individual participant data review.
Nevitt SJ; Marson AG; Tudur Smith C
Cochrane Database Syst Rev; 2018 Oct; 10(10):CD001904. PubMed ID: 30353945
[TBL] [Abstract][Full Text] [Related]
19. Is anticonvulsant treatment of mania a class effect? Data from randomized clinical trials.
Rosa AR; Fountoulakis K; Siamouli M; Gonda X; Vieta E
CNS Neurosci Ther; 2011 Jun; 17(3):167-77. PubMed ID: 20015083
[TBL] [Abstract][Full Text] [Related]
20. Carbamazepine versus phenytoin monotherapy for epilepsy: an individual participant data review.
Nevitt SJ; Marson AG; Tudur Smith C
Cochrane Database Syst Rev; 2019 Jul; 7(7):CD001911. PubMed ID: 31318037
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
